Sotera Health Company $SHC Shares Acquired by Cwm LLC

Cwm LLC grew its position in shares of Sotera Health Company (NASDAQ:SHC) by 1,235.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,330 shares of the company’s stock after purchasing an additional 64,139 shares during the quarter. Cwm LLC’s holdings in Sotera Health were worth $1,223,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Empowered Funds LLC grew its position in Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after buying an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after acquiring an additional 43,471 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares in the last quarter. Creative Planning boosted its stake in shares of Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after acquiring an additional 2,673 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after acquiring an additional 12,758 shares during the period. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Price Performance

Shares of SHC opened at $15.58 on Monday. The stock has a 50 day moving average price of $15.17 and a 200 day moving average price of $16.50. Sotera Health Company has a one year low of $10.68 and a one year high of $19.85. The company has a debt-to-equity ratio of 3.66, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market capitalization of $4.44 billion, a price-to-earnings ratio of 57.71 and a beta of 1.88.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.The company had revenue of $303.44 million for the quarter, compared to analyst estimates of $300.68 million. During the same quarter last year, the firm posted $0.21 EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Equities research analysts forecast that Sotera Health Company will post 0.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the transaction, the director directly owned 12,735,301 shares in the company, valued at approximately $194,468,046.27. The trade was a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 15.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SHC shares. Citigroup lifted their price target on Sotera Health from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Barclays lowered their price target on Sotera Health from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Piper Sandler upgraded Sotera Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $17.00 to $24.00 in a research report on Friday, January 9th. Wells Fargo & Company downgraded Sotera Health to an “overweight” rating in a research note on Thursday, January 8th. Finally, Wall Street Zen lowered Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Sotera Health has a consensus rating of “Moderate Buy” and an average price target of $20.14.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.